Could an arthritis drug stop type 1 diabetes before it starts?

NCT ID NCT07683026

Not yet recruiting Prevention Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This trial tests whether golimumab, a drug used for arthritis, can delay or prevent type 1 diabetes in people who have early signs of the disease but normal blood sugar. Participants receive monthly injections of golimumab or a placebo for up to 6 years. The study tracks how long it takes for blood sugar problems to develop.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Golimumab (Simponi)
What this could lead to: If successful, this could lead to a treatment that delays or prevents the onset of type 1 diabetes in people with early markers of the disease.
What could go wrong: This is a Phase 2 trial, so results are preliminary. Golimumab is an immune-suppressing drug, which may increase infection risk. It may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES (T1D) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 DIABETES (T1D)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Joslin Diabetes Center

Boston, Massachusetts, 02115, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.